We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC50 for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC90 for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups. The oritavancin MBBC50 for S. aureus and S. epidermidis was 2 μg/mL for both the methicillin-resistant and -susceptible subgroups; the MBBC90 for S. aureus and MSSE was 4 μg/mL, and for MRSE, it was 8 μg/mL.
|Original language||English (US)|
|Journal||Diagnostic Microbiology and Infectious Disease|
|State||Accepted/In press - Jan 1 2018|
- Prosthetic joint infection
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases